Prosecution Insights
Last updated: August 06, 2026

Shenzhen Evergreen Therapeutics Co. Ltd.

5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready

Portfolio Summary

5
Total Pending OAs
4
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (2)Due ≤ 30 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

4
Hard (80%)
0
Medium (0%)
1
Easy (20%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§112 only1 (20%)
Multi-statute (no §101)4 (80%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

5
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

50 h
Manual time on pending OAs
10 h
Time saved (low, 20%)
18 h
Time saved (mid, 35%)
0.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
ROMERO, KRISTEN WANG 1 71.1% +29.8%
SHTERENGARTS, SAMANTHA L 1 79.4% +8.0%
LEE, ANDREW P 1 48.5% +23.5%
DAHLIN, HEATHER RAQUEL 1 43.0% +51.7%
MATTISON, LORI K 1 14.7% +26.9%

Hard Cases (4)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
18549968 TREATMENT METHOD FOR INTERSTITIAL PNEUMONIA ROMERO, KRISTEN WANG 24d overdue
17923532 PROGESTOGEN FORMULATIONS AND USES THEREOF LEE, ANDREW P 15d overdue
17623331 APPLICATION OF PROGESTIN IN PREPARATION OF DRUG INHIBITING CYTOKINE STORM DAHLIN, HEATHER RAQUEL 20d
17240698 Treating Auto-Immune and Auto-Inflammatory Diseases MATTISON, LORI K

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
18549968 TREATMENT METHOD FOR INTERSTITIAL PNEUMONIA ROMERO, KRISTEN WANG 24d overdue
17923532 PROGESTOGEN FORMULATIONS AND USES THEREOF LEE, ANDREW P 15d overdue
17623331 APPLICATION OF PROGESTIN IN PREPARATION OF DRUG INHIBITING CYTOKINE STORM DAHLIN, HEATHER RAQUEL 20d
17240698 Treating Auto-Immune and Auto-Inflammatory Diseases MATTISON, LORI K

Top Art Units

Art UnitApps
1624 1
1623 1
1691 1
1629 1
1619 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18549968 TREATMENT METHOD FOR INTERSTITIAL PNEUMONIA ROMERO, KRISTEN WANG 1624 §102§103§112Other Non-Final OA 24d overdue Pending Sep 11, 2023
18254319 USE OF ZANAMIVIR IN PREPARATION OF DRUG FOR TREATING OR PREVENTING PREECLAMPSIA SHTERENGARTS, SAMANTHA L 1623 §112 Non-Final OA Pending May 24, 2023
17923532 PROGESTOGEN FORMULATIONS AND USES THEREOF LEE, ANDREW P 1691 §102§103§112 Non-Final OA 15d overdue Pending Nov 04, 2022
17623331 APPLICATION OF PROGESTIN IN PREPARATION OF DRUG INHIBITING CYTOKINE STORM DAHLIN, HEATHER RAQUEL 1629 §103§112 Final Rejection 20d Pending Dec 28, 2021
17240698 Treating Auto-Immune and Auto-Inflammatory Diseases MATTISON, LORI K 1619 §102§103§112Other Non-Final OA Pending Apr 26, 2021

Managing Shenzhen Evergreen Therapeutics Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month